Abstract

Contrary to popular belief, prostaglandin (PG) E1 and its immediate precursor, dihomogammalinolenic acid (DGLA), are found in physiologically important amounts in humans. PGE1 has many desirable effects, particularly with regard to the cardiovascular system and to inflammation. PGE1 is difficult to use therapeutically because of its short life. Better clinical results may be obtained by administering its precursors such as DGLA and gamma-linolenic acid (GLA).